In this study, to clarify the mechanism of resistance to high-dose anti-VEGFR2 therapy, we applied different doses of VEGFR2 mAb and VEGFR2-tyrosine kinase inhibitor (TKI) in various breast cancer mouse models. The gene discussed is KDR; the disease is breast cancer.